Abstract
Economic analysis aims to help decision makers make better decisions. It is primarily concerned with efficiency: using available resources to maximize achievements in terms of better health and well-being. Cost-effectiveness, cost utility, and cost-benefit analyses are the main tools used by economists for this purpose. Equity is another criterion increasingly recognized as important; equity ensures that access to services and payments for them are distributed fairly across different population groups, with the hope that treatment outcomes might also be more fairly experienced. In this chapter I discuss what decision makers want from economic evaluation and consider some of the uses to which such empirical evidence could be put in the mental health field. These uses – by decision-makers and by others – include lobbying, marketing, comparison, commissioning, health technology appraisal and guidance, policy development, and personalization and empowerment. Each use is illustrated with brief examples.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Slade M. Measuring recovery in mental health services. Isr J Psychiatry Relat Sci. 2010;47(3):206–12.
Mangalore R, Knapp M, Jenkins R. Income-related inequality in mental health in Britain: the concentration index approach. Psychol Med. 2007;37(7):1037–45.
Mangalore R, Knapp M. Income-related inequalities in common mental disorders among ethnic minorities in England. Soc Psychiatry Psychiatr Epidemiol. 2012;47(3):351–9.
Hong J, Knapp M, McGuire A. Income-related inequalities in the prevalence of depression and suicidal behaviour: a 10-year trend following economic crisis. World Psychiatry. 2011;10(1):40–4.
Cookson R, Propper C, Asaria M, Raine R. Socio-economic inequalities in health Care in England. Fisc Stud: J Appl Public Econ. 2016;37(3):371–403.
Cookson R, Mirelman A, Asaria MDB, Griffin S. Fairer decisions, better health for all: health equity and cost-effectiveness analysis. York: Centre for Health Economics, University of York; 2016.
Luyten J, Naci H, Knapp M. Economic evaluation of mental health interventions: an introduction to cost-utility analysis. Evid Based Ment Health. 2016;19(2):49–53.
Layard R, Knapp M, Mayraz G. Cost-benefit analysis of psychological therapy. Natl Inst Econ Rev. 2007;202:90–8.
Knapp M, Patel A, Curran C, Latimer E, Catty J, Becker T, et al. Supported employment: cost-effectiveness across six European sites. World Psychiatry. 2013;12(1):60–8.
Weisbrod BA, Test MA, Stein LI. Alternative to mental hospital treatment. II. Economic benefit-cost analysis. Arch Gen Psychiatry. 1980;37(4):400–5.
Knapp M, Beecham J, Koutsogeorgopoulou V, Hallam A, Fenyo A, Marks IM, et al. Service use and costs of home-based versus hospital-based care for people with serious mental illness. Br J Psychiatry. 1994;165(2):195–203.
Knapp M, Prince M, Albanese E, Baneerjee S, et al. Dementia UK. London: Alzheimer Society; 2007.
Prince M, Comas-Herrera A, Knapp M, et al. Improving healthcare for people living with dementia: coverage, quality and costs now and in the future: world Alzheimer report. London: Alzheimer’s Disease International; 2016.
Banerjee S. The macroeconomics of dementia – will the world economy get Alzheimer’s disease? Arch Med Res. 2012;43:705–9.
Department of Health. Living well with dementia: a National Dementia Strategy. London: Department of Health; 2009.
Lowin A, McCrone P, Knapp M. Alzheimer’s disease in the UK: comparative evidence on cost-of-illness and of health services research funding. Int J Geriatr Psychiatry. 2001;16:1143–8.
Knapp M, Romeo R, Beecham J. Economic cost of autism in the UK. Autism. 2009;13(3):317–36.
Buescher AV, Cidav Z, Knapp M, Mandell DS. Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr. 2014;168(8):721–8.
Simon GE, VonKorff M, Heiligenstein JH, Revicki DA, Grothaus L, Katon W, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA. 1996;275(24):1897–902.
Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther. 1993;15(5):917–26.
Prince M, Wimo A, Guerchet M, et al. The global impact of dementia: world Alzheimer report 2015. London: Alzheimer’s Disease International; 2015.
Evans-Lacko S, Knapp M. Global patterns of workplace productivity for people with depression: absenteeism and presenteeism costs across eight diverse countries. Soc Psychiatry Psychiatr Epidemiol. 2016;51(11):1525–37.
Knapp M, Chisholm D, Astin J, Lelliott P, Audini B. The cost consequences of changing the hospital-community balance: the mental health residential care study. Psychol Med. 1997;27(3):681–92.
Knapp M, Chisholm D, Astin J, Lelliott P, Audini B. Public, private and voluntary residential mental health care: is there a cost difference? J Health Serv Res Policy. 1998;3(3):141–8.
Knapp M, Beecham J, McDaid D, Matosevic T, Smith M. The economic consequences of deinstitutionalisation of mental health services: lessons from a systematic review of European experience. Health Soc Care Community. 2011;19(2):113–25.
Knapp M, Snell T, Healey A, et al. How do child and adolescent mental health problems influence public sector costs? Interindividual variations in a nationally representative British sample. J Child Psychol Psychiatry. 2015;56:667–76.
World Health Organization. The world health report 2000: health systems – improving performance. Geneva: World Health Organization; 2000.
McDaid D, Cookson R. Evaluating health care interventions in the European Union. Health Policy. 2003;63(2):133–9.
Cerri K, Knapp M, Fernandez J. Untangling the complexity of funding recommendations: a comparative analysis of health technology assessment outcomes in four European countries. Pharm Med. 2015;29:341–59.
Knapp M, McDaid D, Parsonage M. Mental health promotion and prevention: the economic case. London: Personal Social Services Research Unit, London School of Economics and Political Science; 2011.
Chisholm D, Sanderson K, Ayuso-Mateos J, Saxena S. Reducing the global burden of depression: population-level analysis of intervention cost effectiveness in 14 world regions. Br J Psychiatry. 2004;184:393–403.
Stevens M, Glendenning C, Jacobs S, et al. Assessing the role of increasing choice in UK social care services. J Soc Policy. 2011;40:257–74.
Forder J, Jones K, Glendenning C, et al. Evaluation of the personal health budget pilot programme. Canterbury: PSSRU; 2012.
Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–5.
Knapp M, Funk M, Curran C, et al. Mental health in low- and middle-income countries: economic barriers to better practice and policy. Health Policy Plan. 2006;21:157–70.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Knapp, M. (2017). Health Economics as a Tool for Decision-Making in Mental Health Care. In: Razzouk, D. (eds) Mental Health Economics. Springer, Cham. https://doi.org/10.1007/978-3-319-55266-8_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-55266-8_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-55265-1
Online ISBN: 978-3-319-55266-8
eBook Packages: MedicineMedicine (R0)